Wird geladen...
Dual targeting of RANKL and PD‐1 with a bispecific antibody improves anti‐tumor immunity
OBJECTIVES: The addition of RANKL/RANK blockade to immune checkpoint inhibitors (ICIs) such as anti‐PD‐1/PD‐L1 and anti‐CTLA4 antibodies is associated with increased anti‐tumor immunity in mice. Recent retrospective clinical studies in patients with advanced melanoma and lung cancer suggest the addi...
Gespeichert in:
| Veröffentlicht in: | Clin Transl Immunology |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
John Wiley and Sons Inc.
2019
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6763724/ https://ncbi.nlm.nih.gov/pubmed/31572609 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cti2.1081 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|